Veeva Systems Shares Drop 19.6% After Strong Q4 Metrics and CRM Transition
Veeva was cited as a detractor in Q4 after beating guidance on all metrics and projecting retention of 14 of its top 20 pharma clients via next-generation CRM. Shares have declined 19.6% in one month and 20.3% year-over-year, and the company holds a $29.6 billion market cap.
1. Q4 Detractor Despite Strong Results
In Q4 2025, the fund highlighted Veeva as a detractor despite the company exceeding guidance and consensus across all financial metrics, underscoring investor concerns over upcoming client transitions.
2. Next-Generation CRM Client Retention
Veeva expects to retain 14 of its top 20 global pharma clients as they migrate to its next-generation CRM platform, a key driver for long-term subscription revenue and cross-sell opportunities in regulated content management.
3. Stock Decline and Valuation
Shares have fallen 19.6% over the past month and 20.3% year-over-year, while Veeva maintains a $29.6 billion market capitalization, indicating market reevaluation of near-term growth prospects.